<doc:document xmlns:doc="http://www.elsevier.com/xml/document/schema" xmlns:dp="http://www.elsevier.com/xml/common/doc-properties/schema" xmlns:cps="http://www.elsevier.com/xml/common/consyn-properties/schema" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dct="http://purl.org/dc/terms/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:oa="http://vtw.elsevier.com/data/ns/properties/OpenAccess-1/" xmlns:bam="http://vtw.elsevier.com/data/voc/ns/bam-vtw-1/" xmlns:cp="http://vtw.elsevier.com/data/ns/properties/Copyright-1/" xmlns:cja="http://www.elsevier.com/xml/cja/schema" xmlns:ja="http://www.elsevier.com/xml/ja/schema" xmlns:bk="http://www.elsevier.com/xml/bk/schema" xmlns:ce="http://www.elsevier.com/xml/common/schema" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:cals="http://www.elsevier.com/xml/common/cals/schema" xmlns:tb="http://www.elsevier.com/xml/common/table/schema" xmlns:sa="http://www.elsevier.com/xml/common/struct-aff/schema" xmlns:sb="http://www.elsevier.com/xml/common/struct-bib/schema" xmlns:xlink="http://www.w3.org/1999/xlink"><rdf:RDF><rdf:Description rdf:about="http://dx.doi.org/10.1016/j.bbadva.2021.100032"><dct:format>application/xml</dct:format><dct:title>Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses</dct:title><dct:creator>Graeme Benzie</dct:creator><dct:creator>Kristen Bouma</dct:creator><dct:creator>Taylor Battellino</dct:creator><dct:creator>Steven Cooper</dct:creator><dct:creator>Rick Hemming</dct:creator><dct:creator>Wafa Kammouni</dct:creator><dct:creator>Lin Liu</dct:creator><dct:creator>Cuong Do</dct:creator><dct:creator>Mazdak Khajehpour</dct:creator><dct:creator>Helene Perreault</dct:creator><dct:creator>Stuart Kornfeld</dct:creator><dct:creator>Barbara Triggs-Raine</dct:creator><dct:creator>Brian L. Mark</dct:creator><dct:description>BBA Advances, Journal Pre-proof. doi:10.1016/j.bbadva.2021.100032</dct:description><prism:aggregationType>journal</prism:aggregationType><prism:publicationName>BBA Advances</prism:publicationName><prism:copyright>&#169; 2021 The Authors. Published by Elsevier B.V.</prism:copyright><dct:publisher>Elsevier B.V.</dct:publisher><prism:issn>2667-1603</prism:issn><prism:doi>10.1016/j.bbadva.2021.100032</prism:doi><prism:url>http://dx.doi.org/10.1016/j.bbadva.2021.100032</prism:url><dct:identifier>doi:10.1016/j.bbadva.2021.100032</dct:identifier><bam:articleNumber>100032</bam:articleNumber><oa:openAccessInformation><oa:openAccessStatus xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://vtw.elsevier.com/data/voc/oa/OpenAccessStatus#Full</oa:openAccessStatus><oa:openAccessEffective xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">2021-12-09T19:38:10Z</oa:openAccessEffective><oa:sponsor xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><oa:sponsorType>http://vtw.elsevier.com/data/voc/oa/SponsorType#FundingBody</oa:sponsorType><oa:sponsorName>Canada: LE Tracking</oa:sponsorName></oa:sponsor><oa:userLicense xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">http://creativecommons.org/licenses/by-nc-nd/4.0/</oa:userLicense></oa:openAccessInformation><cp:licenseLine xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">This is an open access article under the CC BY-NC-ND license.</cp:licenseLine></rdf:Description></rdf:RDF><dp:document-properties><dp:aggregation-type>Journals</dp:aggregation-type><dp:version-number>S5.1</dp:version-number></dp:document-properties><ja:article docsubtype="fla" version="5.6" xml:lang="en"><ja:item-info><ja:jid>BBADVA</ja:jid><ja:aid>100032</ja:aid><ce:article-number>100032</ce:article-number><ce:pii>S2667-1603(21)00031-4</ce:pii><ce:doi>10.1016/j.bbadva.2021.100032</ce:doi><ce:copyright type="unknown" year="2021"/></ja:item-info><ja:head><ce:title id="tte0002">Increased phosphorylation of HexM improves lysosomal uptake and potential for managing GM2 gangliosidoses</ce:title><ce:author-group id="aut0001"><ce:author id="au0001" author-id="S2667160321000314-b605c5c7f32b6eb2e24a072592064c90"><ce:given-name>Graeme</ce:given-name><ce:surname>Benzie</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="fn1"><ce:sup loc="post">+</ce:sup></ce:cross-ref></ce:author><ce:author id="au0002" author-id="S2667160321000314-9841227d7db1aa7aa8a1aca5c4a28a2f"><ce:given-name>Kristen</ce:given-name><ce:surname>Bouma</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="fn1"><ce:sup loc="post">+</ce:sup></ce:cross-ref></ce:author><ce:author id="au0003" author-id="S2667160321000314-2c048eb312f68d9121fdad0e7ef5f3c0"><ce:given-name>Taylor</ce:given-name><ce:surname>Battellino</ce:surname><ce:cross-ref refid="aff0002"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0004" author-id="S2667160321000314-8116bfeb16a7247c2b0ba74de0be6b0f"><ce:given-name>Steven</ce:given-name><ce:surname>Cooper</ce:surname><ce:cross-ref refid="aff0003"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0005" author-id="S2667160321000314-3c6b2b0ab9edefbe9bea197f97e60ee8"><ce:given-name>Rick</ce:given-name><ce:surname>Hemming</ce:surname><ce:cross-ref refid="aff0003"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0006" author-id="S2667160321000314-fe64535ef521969ce40f43e3d85122fd"><ce:given-name>Wafa</ce:given-name><ce:surname>Kammouni</ce:surname><ce:cross-ref refid="aff0003"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0007" author-id="S2667160321000314-f6389ae53967f0a3c05e2bdeeb47e238"><ce:given-name>Lin</ce:given-name><ce:surname>Liu</ce:surname><ce:cross-ref refid="aff0004"><ce:sup loc="post">d</ce:sup></ce:cross-ref></ce:author><ce:author id="au0008" author-id="S2667160321000314-66704a0e5ef990b7e129ead282b49256"><ce:given-name>Cuong</ce:given-name><ce:surname>Do</ce:surname><ce:cross-ref refid="aff0004"><ce:sup loc="post">d</ce:sup></ce:cross-ref></ce:author><ce:author id="au0009" author-id="S2667160321000314-15ce65d7c84f2e5aaa8cbc2ef2fa1eed"><ce:given-name>Mazdak</ce:given-name><ce:surname>Khajehpour</ce:surname><ce:cross-ref refid="aff0002"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0010" author-id="S2667160321000314-0155294f5935e04425c831f87e7a7b84"><ce:given-name>Helene</ce:given-name><ce:surname>Perreault</ce:surname><ce:cross-ref refid="aff0002"><ce:sup loc="post">b</ce:sup></ce:cross-ref></ce:author><ce:author id="au0011" author-id="S2667160321000314-583837fc3298d8ecc1e385a3d8349114"><ce:given-name>Stuart</ce:given-name><ce:surname>Kornfeld</ce:surname><ce:cross-ref refid="aff0005"><ce:sup loc="post">e</ce:sup></ce:cross-ref></ce:author><ce:author id="au0012" author-id="S2667160321000314-e090d7d01b913e0717803d41669b04d7"><ce:given-name>Barbara</ce:given-name><ce:surname>Triggs-Raine</ce:surname><ce:cross-ref refid="aff0003"><ce:sup loc="post">c</ce:sup></ce:cross-ref></ce:author><ce:author id="au0013" author-id="S2667160321000314-480b3943e907cca90150dd1dd394e967"><ce:given-name>Brian L.</ce:given-name><ce:surname>Mark</ce:surname><ce:cross-ref refid="aff0001"><ce:sup loc="post">a</ce:sup></ce:cross-ref><ce:cross-ref refid="cor0001"><ce:sup loc="post">&#x204e;</ce:sup></ce:cross-ref><ce:e-address id="ead0001" type="email" xlink:href="mailto:Brian.Mark@umanitoba.ca">Brian.Mark@umanitoba.ca</ce:e-address></ce:author><ce:affiliation id="aff0001" affiliation-id="S2667160321000314-d8453eaa07811473e97688d34ebf044e"><ce:label>a</ce:label><ce:textfn id="cetextfn0001">Department of Microbiology, University of Manitoba, Winnipeg, Canada, R3T 2N2</ce:textfn><sa:affiliation><sa:organization>Department of Microbiology</sa:organization><sa:organization>University of Manitoba</sa:organization><sa:city>Winnipeg</sa:city><sa:postal-code>R3T 2N2</sa:postal-code><sa:country>Canada</sa:country></sa:affiliation><ce:source-text id="staff0001">aDepartment of Microbiology, University of Manitoba, Winnipeg, Canada, R3T 2N2</ce:source-text></ce:affiliation><ce:affiliation id="aff0002" affiliation-id="S2667160321000314-0c062c1c3a03e9edda242be7749cd574"><ce:label>b</ce:label><ce:textfn id="cetextfn0002">Department of Chemistry, University of Manitoba, Winnipeg, Canada, R3T 2N2</ce:textfn><sa:affiliation><sa:organization>Department of Chemistry</sa:organization><sa:organization>University of Manitoba</sa:organization><sa:city>Winnipeg</sa:city><sa:postal-code>R3T 2N2</sa:postal-code><sa:country>Canada</sa:country></sa:affiliation><ce:source-text id="staff0002">bDepartment of Chemistry, University of Manitoba, Winnipeg, Canada, R3T 2N2</ce:source-text></ce:affiliation><ce:affiliation id="aff0003" affiliation-id="S2667160321000314-097b1ba13dc247f7414689f549c8668e"><ce:label>c</ce:label><ce:textfn id="cetextfn0003">Biochemistry and Medical Genetics; University of Manitoba</ce:textfn><sa:affiliation><sa:organization>Biochemistry and Medical Genetics</sa:organization><sa:organization>University of Manitoba</sa:organization></sa:affiliation><ce:source-text id="staff0003">cBiochemistry and Medical Genetics; University of Manitoba</ce:source-text></ce:affiliation><ce:affiliation id="aff0004" affiliation-id="S2667160321000314-d1f9fd4458d7fb251875fe8323c904b8"><ce:label>d</ce:label><ce:textfn id="cetextfn0004">M6P Therapeutics, 20 S. Sarah St., St. Louis, MO, 63018, USA</ce:textfn><sa:affiliation><sa:organization>M6P Therapeutics</sa:organization><sa:address-line>20 S. Sarah St.</sa:address-line><sa:city>St. Louis</sa:city><sa:state>MO</sa:state><sa:postal-code>63018</sa:postal-code><sa:country>USA</sa:country></sa:affiliation><ce:source-text id="staff0004">dM6P Therapeutics, 20 S. Sarah St., St. Louis, MO, 63018, USA</ce:source-text></ce:affiliation><ce:affiliation id="aff0005" affiliation-id="S2667160321000314-98e2b76134f12209a405239a852e5fc9"><ce:label>e</ce:label><ce:textfn id="cetextfn0005">Washington University School of Medicine in St. Louis, Department of Biochemistry &amp; Molecular Biophysics</ce:textfn><sa:affiliation><sa:organization>Washington University School of Medicine in St. Louis</sa:organization><sa:organization>Department of Biochemistry &amp; Molecular Biophysics</sa:organization></sa:affiliation><ce:source-text id="staff0005">eWashington University School of Medicine in St. Louis, Department of Biochemistry &amp; Molecular Biophysics</ce:source-text></ce:affiliation><ce:correspondence id="cor0001"><ce:label>&#x204e;</ce:label><ce:text id="cetext0001">Correspondence author: Brian Mark, Microbiology, Biochemistry &amp; Medical Genetics, University of Manitoba, Winnipeg, MB, Canada</ce:text><sa:affiliation><sa:organization>Microbiology, Biochemistry &amp; Medical Genetics</sa:organization><sa:organization>University of Manitoba</sa:organization><sa:city>Winnipeg</sa:city><sa:state>MB</sa:state><sa:country>Canada</sa:country></sa:affiliation></ce:correspondence><ce:footnote id="fn1"><ce:label>+</ce:label><ce:note-para id="notep0001" view="all">These authors contributed equally to this work</ce:note-para></ce:footnote></ce:author-group><ce:abstract id="abs0001" class="author-highlights" view="all"><ce:section-title id="cesectitle0001">Highlights</ce:section-title><ce:abstract-sec id="abss0001" view="all"><ce:simple-para id="spara007" view="all"><ce:list id="celist0001"><ce:list-item id="celistitem0001"><ce:label>&#x2022;</ce:label><ce:para id="para0002" view="all">Tay-Sachs and Sandhoff disease are caused by loss of &#x03b2;-hexosaminidase A (HexA).</ce:para></ce:list-item><ce:list-item id="celistitem0002"><ce:label>&#x2022;</ce:label><ce:para id="para0003" view="all">Scalable production of a stable version of HexA, known as HexM, provides potential for an enzyme replacement therapy.</ce:para></ce:list-item><ce:list-item id="celistitem0003"><ce:label>&#x2022;</ce:label><ce:para id="para0004" view="all">Phosphorylation of HexM by an engineered GlcNAc-1-phosphotransferase significantly enhances cellular uptake.</ce:para></ce:list-item></ce:list></ce:simple-para></ce:abstract-sec></ce:abstract><ce:abstract id="abs0002" view="all" class="author"><ce:section-title id="cesectitle0002">Abstract</ce:section-title><ce:abstract-sec id="abss0002" view="all"><ce:simple-para id="spara008" view="all">Tay-Sachs and Sandhoff diseases are genetic disorders resulting from mutations in <ce:italic>HEXA</ce:italic> or <ce:italic>HEXB</ce:italic>, which code for the &#x03b1;- and &#x03b2;-subunits of the heterodimer &#x03b2;-hexosaminidase A (HexA), respectively. Loss of HexA activity results in the accumulation of GM2 ganglioside (GM2) in neuronal lysosomes, culminating in neurodegeneration and death, often by age 4. Previously, we combined critical features of the &#x03b1;- and &#x03b2;-subunits of HexA into a single subunit to create a homodimeric enzyme known as HexM. HexM is twice as active as HexA and degrades GM2 <ce:italic>in vivo</ce:italic>, making it a candidate for enzyme replacement therapy (ERT). Here we show HexM production is scalable to meet ERT requirement and we describe an approach that enhances its cellular uptake via co-expression with an engineered GlcNAc-1-phosphotransferase that highly phosphorylates lysosomal proteins. Further, we developed a HexA overexpression system and functionally compared the recombinant enzyme to HexM, revealing the kinetic differences between the enzymes. This study further advances HexM as an ERT candidate and provides a convenient system to produce HexA for comparative studies.</ce:simple-para></ce:abstract-sec></ce:abstract></ja:head></ja:article></doc:document>
